ACM
PBYI icon

Advent Capital Management’s Puma Biotechnology PBYI Stock Holding History

Advent Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,500
Closed -$676K – 470
2014
Q2 		$676K Buy
+2,500
New +$178K 0.01% 398

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Advent Capital Management's PBYI Position: Q3 2014 in Review

Advent Capital Management sold out of Puma Biotechnology (PBYI) in Q3 2014, closing a stake of 2,500 shares — an estimated $676K sold.

Advent Capital Management first reported a position in PBYI in Q2 2014 and held it in 1 quarter. The position peaked at $676K in Q2 2014. 183 funds tracked by Wall St. Rank hold PBYI as of Q3 2014.

  • Advent Capital Management reported no remaining Puma Biotechnology position as of Q3 2014 after selling out during the quarter.
  • Advent Capital Management sold 2,500 Puma Biotechnology shares in Q3 2014, an estimated $676K.
  • Advent Capital Management first reported a position in Puma Biotechnology in Q2 2014 and held it in 1 quarter.
  • Advent Capital Management's Puma Biotechnology position peaked at $676K in Q2 2014.
  • 183 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2014.

Based on Advent Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.